Keytruda Resistant TIL and Tumor co-culture
$9,000.00Description
Tumor infiltrating lymphocytes (TILs) are immune cells that have migrated into the tumor environment in order to attach cancer cells. TILs are comprised of immune sub-populations that play various roles in the immune-tumor interactions. TILs are removed from a patient’s tumor and are then treated in the laboratory with substances that activate the lymphocytes to help them better kill the patient’s cancer cells (source: NCI).
Using our Keytruda resistant TIL and Tumor cell line, this assay attempts to screen drug candidates in comparison with Keytruda (anti-PD1) therapy.
What is the assay setup?
- Co-culture tumor and TIL for 24 hours in the presence of drug candidate
- After 24 hours harvest the supernatants
- Measure cytokine release and tumor lysis
What are the study arms?
- TIL + Tumor+ Keytruda (anti-PD1)
- TIL + Tumor+ <drug candidate (per dose)>
- TIL + Tumor
- TIL + Tumor + DMSO
- TIL
- Tumor
How many doses are included?
The assay is run in a 96 well plate and can accommodate up to 40 doses of the drug candidate. Each dose is a well.
What is included the price?
- Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
- Assay setup and methods used
- Raw data files for cytokines
When can I expect results?
We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.
